Vera Therapeutics, Inc. (VERA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Vera Therapeutics reported revenue of $0. Net income was -$299.6M, or -$4.66 per diluted share. Operating activities generated -$241.1M of cash, leaving -$241.7M of free cash flow. At fiscal year end, Vera Therapeutics held $734.7M in total assets against $130.2M in total liabilities, including $354.7M of cash and equivalents.
Open the full interactive Vera Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Vera Therapeutics Key Stats
| Share Price | $26.79 |
|---|---|
| Market Cap | $1.92B |
| 52-Week Range | $24.10 – $55.67 |
| Shares Outstanding | 71.8 million (basic, 2026 Q2) |
Vera Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$34.4M | -$90.9M | -$102.0M | -$167.2M | -$315.5M |
| Pre-Tax Income | -$32.6M | -$89.1M | -$96.0M | -$152.1M | -$299.6M |
| Income Tax | -$1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Net Income | -$32.6M | -$89.1M | -$96.0M | -$152.1M | -$299.6M |
| Diluted EPS | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 |
Vera Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$80.3M | -$91.1M | -$121.0M | -$109.5M |
| Diluted EPS | -$1.26 | -$1.42 | -$1.69 | -$1.52 |
Vera Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $79.7M | $43.5M | $45.7M | $92.6M | $354.7M |
| Current Assets | $82.5M | $125.7M | $172.0M | $651.2M | $728.9M |
| Total Assets | $83.7M | $131.4M | $175.5M | $655.7M | $734.7M |
| Current Liabilities | $7.7M | $25.6M | $22.3M | $25.4M | $53.5M |
| Total Long-Term Debt | $4.9M | $24.8M | $49.9M | $50.7M | $74.8M |
| Total Liabilities | $14.2M | $54.5M | $73.9M | $78.5M | $130.2M |
| Shareholders' Equity | $69.6M | $76.9M | $101.7M | $577.2M | $604.5M |
Vera Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$23.7M | -$67.6M | -$92.2M | -$134.7M | -$241.1M |
| Cash From Investing | -$4.2M | -$70.6M | -$39.4M | -$425.0M | $194.3M |
| Cash From Financing | $53.9M | $101.9M | $133.5M | $606.7M | $308.9M |
| Free Cash Flow | -$23.8M | -$67.7M | -$92.2M | -$135.7M | -$241.7M |
Figures from Vera Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vera Therapeutics financials page for every line item.
Vera Therapeutics Company Profile
| Ticker | VERA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Brisbane, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001831828 |
Frequently Asked Questions
What was Vera Therapeutics' revenue in fiscal 2025?
Vera Therapeutics (VERA) reported revenue of $0 for fiscal 2025.
What is Vera Therapeutics' annual revenue history?
Vera Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Vera Therapeutics' net income in fiscal 2025?
Vera Therapeutics reported net income of -$299.6M for fiscal 2025.
What was Vera Therapeutics' earnings per share (EPS) in fiscal 2025?
Vera Therapeutics' diluted EPS was -$4.66 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vera Therapeutics generate in fiscal 2025?
Vera Therapeutics generated -$241.7M of free cash flow in fiscal 2025.
What was Vera Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Vera Therapeutics reported revenue of $0.
How much debt does Vera Therapeutics have?
Vera Therapeutics reported $74.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Vera Therapeutics are outstanding?
Vera Therapeutics reported a weighted average of 71.8 million basic shares outstanding in 2026 Q2.
What is Vera Therapeutics' market cap?
Based on its latest closing price, Vera Therapeutics (VERA) has a market capitalization of about $1.92B.
When does Vera Therapeutics' fiscal year end?
Vera Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Vera Therapeutics headquartered?
Vera Therapeutics lists its business address in Brisbane, California in its SEC filings.